Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
BIG 02/98 Docetaxel - Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2887
- Registration Number
- NCT00174655
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford Surrey, United Kingdom
EXIBIT: Oxaliplatin in Biliary Tract Cancer
- Conditions
- Biliary Tract Neoplasms
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT00174564
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 118
- Registration Number
- NCT00174798
- Locations
- 🇺🇸
Hudson Valley Urology Center, Kingston, New York, United States
🇺🇸Hudson Valley Urology, Poughkeepsie, New York, United States
🇺🇸Rockhill Medical Plaza, Kansas City, Missouri, United States
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00174837
- Locations
- 🇳🇿
sanofi-aventis New Zealand administrative office, Macquarie Park, New Zealand
🇨🇳Sanofi-Aventis Administrative Office, Taipei, Taiwan
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
- Conditions
- Arterial Occlusive Diseases
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1460
- Registration Number
- NCT00174759
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00174681
- Locations
- 🇸🇮
Sanofi-Aventis, Ljubljana, Slovenia
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
- Conditions
- Prostatic Neoplasm
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 232
- Registration Number
- NCT00174863
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
- Conditions
- Rectal Neoplasms
- Interventions
- Drug: Oxaliplatin, capecitabine, radiotherapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87
- Registration Number
- NCT00174616
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00174772
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guilford, United Kingdom
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
- Conditions
- Atrial FibrillationAtrial Flutter
- Interventions
- Drug: dronedarone (SR33589)Drug: placebo
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4628
- Registration Number
- NCT00174785
- Locations
- 🇩🇪
Sanofi-aventis Administrative Office, Berlin, Germany
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom